This article is more than 5 years old. Information may no longer be current.

Regeneron total revenues increased by 22% to $726 million in Q3

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Regeneron reported total revenues of $726 million for the third quarter of 2014, compared with $597 million 1 year ago, according to a company press release.

Third-quarter net product sales were $449 million, compared with $367 million in the third quarter of 2013. In the U.S., Eylea (aflibercept) net product sales were $445 million in the third quarter of 2014, compared with $363 million in last year’s third quarter.

Total revenues also included collaboration revenues of $269 million in the third quarter of 2014, compared with $223 million in the third quarter of last year. These revenues increased based on the company’s net profit from commercialization of Eylea outside of the U.S., according to the press release.

Regeneron reported a non-GAAP net income of $295 million, or $2.93 per basic share

and $2.52 per diluted share, up 6% from last year’s non-GAAP net income of $277 million, or $2.82 per basic share and $2.40 per diluted share, according to the release.

Third-quarter 2014 GAAP net income was $80 million, or $0.79 per basic share and $0.70 per diluted share, compared with $141 million, or $1.44 per basic share and $1.25 per diluted share, in the third quarter of 2013.